Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety and Efficacy of the Mynx Control Venous Vascular Closure Device 6F-12F vs Manual Compression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18~2. Able and willing to provide informed consent and to complete a follow-up visit at 30 days~3. Planned catheter-based procedures via the common femoral vein(s) using up 6F to 12F introducer sheaths which meet indications for elective, nonemergent interventions of disease state, without contraindications for emergent vascular surgery or manual compression of the venous access sites~Exclusion Criteria:~1. Any use of systemic steroids (IV or oral) within 30 days of procedure~2. History of deep vein thrombosis, pulmonary embolism, or thrombophlebitis within 6 months of procedure~3. Presence of thrombocytopenia (platelet count \< 100,000 cells/mm3) or anemia (hemoglobin \< 10 g/dL, hematocrit \< 30%)~4. History of bleeding disorders such hemophilia or von Willebrand's disease~5. Currently involved in any other investigational clinical trial~6. Documented history of uncontrolled hypertension (i.e., systolic blood pressure \> 180 mm Hg), or critical illness requiring intravenous vasopressors for blood pressure stabilization~7. Femoral arteriotomy or venotomy in either limb within 10 days pre procedure~8. Use of VCD in either limb within 30 days of procedure~9. Any planned procedure involving femoral arterial or venous access in either limb within 30 days or prior to study exit~10. Renal insufficiency (i.e., serum creatinine \> 2.5 mg/dL)~11. Patients who are pregnant, planning to become pregnant during the study period, or lactating~12. Body-mass index (BMI) \> 45 kg/m2 or \<20 kg/m2~13. Unable to routinely walk at least 20 feet without assistance~14. Known allergy/adverse reaction to polyethylene glycol or contrast medium~15. Planned procedures (including staged) or concomitant conditions/comorbidities that per investigator's judgment may extend ambulation attempts beyond 2-3 hours, and/or require extended hospitalization or re-hospitalization~16. Previous vascular surgery or repair in the vicinity of the target access site within the previous 90 days of the procedure~17. Active systemic infection, or cutaneous infection or inflammation in the vicinity of the target access site~18. Current COVID-19 infection (with or without symptoms), positive test for COVID- 19 within 14 days, or recent exposure to a person with COVID-19 infection~19. Patients who refuse blood transfusion if it were to be needed~20. Patients with expected life of less than 30 days~Intra-Procedural Exclusion Criteria~Patients who meet any of the following criteria during the index procedure will be excluded:~1. Any attempt at femoral arterial access or inadvertent arterial puncture with hematoma during the procedure~2. Any procedural complications that may interfere with routine recovery, ambulation, or discharge eligibility times~3. Physician deems that a different hemostasis approach for venous access sites is necessary~4. Physician deems that the subject should not attempt protocol required ambulation (reference ambulation protocol per section 14.2)~5. Venous access site location is noted to be above the inguinal ligament (cephalad to lower half of the femoral head or the inferior epigastric vein origin from the external iliac vein)~6. Intra-procedural bleeding around sheath, or suspected intraluminal thrombus, hematoma, pseudoaneurysm, or AV fistula~7. Difficult insertion of procedural sheath or needle stick problems at the onset of the procedure (e.g., multiple stick attempts, accidental arterial stick with hematoma, back wall stick, etc.)~8. A \< 6F or \> 12F procedural sheath is present at any time during the procedure or at closure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mynx Control Venous Closure (Type: EXPERIMENTAL): 204 (2:1 randomized - 136 VCD:68 manual compression)
- Manual Compression (Type: ACTIVE_COMPARATOR): 204 (2:1 randomized - 136 VCD:68 manual compression)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete